Therefore, it could be asked whether some CRC cells harboring inactivating mutations in components of the canonical TGFβ signaling cascade maintain TGFβ responsiveness, for instance via alternative SMAD-independent pathways (e.g. ERK, p38) that are intact in most cancer cell types 9, 10. Here, TGFB1 is linked to cancer.